Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Arthritis Life

What do People with Rheumatoid Arthritis Need to Know about COVID-19 in 2024?

22 Apr 2024

Description

Dr Dave & Dr Campbell answer Cheryl’s burning questions about long COVID, vaccine efficacy and safety for people with autoimmune conditions, and potential links between autoimmunity and long COVID. They also talk about cutting edge research and new therapies including CAR T-cell therapy.Dr. Campbell encourages participation in research studies to better understand these complex issues. Dr. Dave emphasizes the need for precision medicine approaches in treating autoimmune diseases like RA, where individualized treatment plans can be tailored to each patient's unique needs. Despite the challenges posed by autoimmune diseases and COVID-19, they express optimism about the future of treatment options and the ongoing medical advancements.Medical disclaimer: All content found on Arthritis Life public channels was created for generalized informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment.Episode SponsorsRheum to THRIVE, an online course and support program Cheryl created to help people with rheumatic disease go from overwhelmed, confused and alone to confident, supported and connected. See all the details and join the program or waitlist now! For full episode details including a transcript & videoGo to the episode post on the Arthritis Life Website (page coming soon)!  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.